Ipamorelin is a synthetic growth hormone releasing peptide that stimulates pulsatile GH secretion from the pituitary gland. Using it correctly requires precise dosing, proper timing, and evaluation by a licensed provider — available asynchronously at TelosRX.
Ipamorelin is not FDA-approved for any human therapeutic use. All use is subject to medical approval by a licensed provider. This guide covers the protocol steps commonly referenced in clinical and research literature; your provider's instructions take precedence over any general guidance.
Step 1: Understand What Ipamorelin Is — and Is Not
Ipamorelin is a pentapeptide growth hormone releasing peptide (GHRP) that selectively stimulates the pituitary to release GH without meaningfully elevating cortisol, prolactin, or ACTH. This selectivity distinguishes it from earlier GHRPs like GHRP-2 and GHRP-6. A foundational study published in Growth Hormone & IGF Research (1998) confirmed ipamorelin's selective GH-releasing action in animal models, with a clean hormonal profile at standard doses.
Ipamorelin is frequently combined with a growth hormone releasing hormone (GHRH) analogue — such as CJC-1295 — to generate a synergistic GH pulse. It is also compared against secretagogues like MK-677 (an oral option) and sermorelin (a GHRH-class analogue). Which approach is appropriate depends on your goals and a provider's clinical assessment of your baseline.
Step 2: Complete a Provider Evaluation Before Starting
Ipamorelin is a compounded medication. It is subject to medical approval by a licensed provider and cannot be legally self-prescribed. Do not adjust dosing, cycle length, or injection frequency without direct provider guidance.
At TelosRX, the process is fully asynchronous — you submit a health history questionnaire and relevant lab values through the patient portal, and a licensed provider reviews your file on their own schedule. There are no required video calls or synchronous appointments. Approval is not guaranteed; providers make an independent clinical determination for each patient. Only proceed with the steps below after a licensed provider has reviewed your file and issued a prescription.
Step 3: Know the Standard Dosing Range
The ranges below reflect protocols described in the published literature. Your provider may prescribe a different dose based on your individual presentation, labs, and goals.
| Parameter | Common Range |
|---|---|
| Dose per injection | 100–300 mcg |
| Injections per day | 1–3 |
| Cycle length | 8–16 weeks |
| Administration route | Subcutaneous injection |
| Typical starting dose | 100–200 mcg, once nightly |
Increasing dose beyond the prescribed range does not proportionally increase GH output and may increase the likelihood of side effects without added clinical benefit.
Step 4: Reconstitute the Peptide Correctly
Ipamorelin is dispensed as a lyophilized (freeze-dried) powder requiring reconstitution with bacteriostatic water. Follow your pharmacy's specific instructions. The standard procedure is:
- Wash hands thoroughly. Prepare a clean, flat workspace.
- Bring both the peptide vial and bacteriostatic water vial to room temperature.
- Wipe both vial stoppers with an alcohol swab. Allow to air dry completely.
- Draw the prescribed volume of bacteriostatic water into a sterile insulin syringe.
- Insert the needle into the peptide vial and inject the water slowly along the inner vial wall — do not spray directly onto the powder cake.
- Gently swirl (do not shake) until the powder dissolves completely. The solution should be clear and colorless.
- Label the vial with the reconstitution date. Store refrigerated at 36–46°F (2–8°C) and use within 30 days. Discard any vial that appears cloudy, discolored, or contains visible particles.
Step 5: Time Your Injections for Maximum Effect
GH is released in pulses. Strategic injection timing avoids competing with periods of natural GH suppression:
- Before sleep: The largest endogenous GH pulse occurs during slow-wave sleep. Injecting 30–60 minutes before bed may amplify this pulse.
- Morning fasted: Insulin suppresses GH secretion. Injecting before eating — in a fasted state — avoids glucose-mediated blunting of the GH response.
- Post-exercise: Exercise produces a natural GH spike. A third injection in the post-workout window (fasted or low-carbohydrate) is used in some multi-dose protocols.
As a general principle, avoid injecting within 2 hours of a high-carbohydrate meal. Elevated blood glucose and insulin significantly reduce the effectiveness of any GH-releasing peptide.
Step 6: Recognize Potential Side Effects
Ipamorelin is associated with a favorable side effect profile relative to exogenous GH, but adverse effects can occur. Commonly reported effects include:
- Injection site reactions: Transient redness, mild swelling, or tenderness at the injection site.
- Headache or lightheadedness: Associated with rapid GH release, particularly at higher doses. Typically resolves within minutes.
- Mild water retention: Edema can occur during the early weeks of a protocol, often resolving as the body adjusts.
- Tingling or numbness: Particularly in the hands and wrists — a known correlate of elevated IGF-1. Usually transient.
- Increased appetite: Less pronounced than with GHRP-6, but reported in some users at higher doses.
Because ipamorelin is not FDA-approved for any human therapeutic use, long-term safety data in humans remains limited. Report any persistent or concerning symptoms to your provider promptly. For a summary of the published evidence base, see the independent review at Examine.com's ipamorelin research page.
Step 7: Monitor Your Response and Follow Up With Your Provider
Effective ipamorelin use involves ongoing monitoring, not a one-time prescription. Key markers typically tracked throughout a protocol include:
- IGF-1: The primary biomarker for GH axis activity. Measured at baseline and mid-cycle to assess response.
- Fasting glucose and insulin: To screen for glucose regulation changes.
- Subjective outcomes: Sleep quality, recovery, body composition trajectory, and energy levels.
TelosRX operates as an asynchronous telehealth service. Follow-up is conducted through the patient portal — you submit labs and symptom updates, and your licensed provider reviews them on their schedule. Providers may modify or discontinue a prescription based on follow-up data. Approval at initiation does not guarantee continuation of a protocol.
Frequently Asked Questions
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved for any human therapeutic use. It is available as a compounded medication prepared under federal compounding regulations and is prescribed off-label by licensed providers where clinically appropriate.
How long before I see results from ipamorelin?
Improvements in sleep quality are often reported within the first 2–4 weeks. Measurable body composition changes — such as shifts in lean mass and fat distribution — typically appear after 8–12 weeks of consistent protocol adherence. Individual results vary and are not guaranteed.
Can I use ipamorelin without combining it with CJC-1295?
Yes. Ipamorelin functions as a standalone peptide. Combining it with a GHRH analogue like CJC-1295 produces a larger synergistic GH pulse, but many protocols use ipamorelin alone. Your licensed provider will determine the appropriate approach for your clinical picture.
How should I store reconstituted ipamorelin?
Store refrigerated at 36–46°F (2–8°C). Use within 30 days of reconstitution. Do not freeze the reconstituted solution. Protect from light and temperature extremes.
What time of day should I inject ipamorelin?
The most commonly used timing is 30–60 minutes before sleep, aligned with the body's largest natural GH pulse. Some protocols add a morning fasted injection or a post-exercise dose. Follow your provider's specific instructions for your protocol.
Does ipamorelin raise cortisol or prolactin?
At standard doses, ipamorelin does not significantly elevate cortisol, prolactin, or ACTH — a selectivity profile that distinguishes it from earlier GHRPs. This is one reason ipamorelin has remained a preferred research peptide for GH stimulation studies.
Start your private evaluation at TelosRX.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.